Biotech Values

[WID]

I have read a few opinions in here and I just try to put up a quick opinion of myself to get your comments.

First, I think that MNTA does not want to create any controversial relationship with FDA so they do something to view as they are clueless about what happens on TEVA application on the t-lovenox front and MNTA application on the m-Cop.

Rasing more capital is not a famous thing to do with existing shareholders but it is not a bad thing either.

So, why MNTA wants to raise more capital at the time that no one will think that they ever need capital for general business purposes?

If MNTA knows for sure that t-lovenox never gets approved and they just sit there to collect revenue and share profits with NVS, this will make both MNTA and FDA looks bad--because Amphastar and/or TEVA will think that MNTA have internal info from FDA-- That will make both MNTA and FDA look bad... Amphastar already filed complains about MNTA/FDA relationships and TEVA has been whining on the m-lovenox applications.

In order to be fair and balanced, MNTA will do the unthinkable things by raising more capital for general purposes. By doing this, MNTA will preempt complains from both TEVA, Amphastar and/or Mylan (if m-Copaxone gets the nod soon). All the suspicious relationships between MNTA and FDA will cool down for the time being while shareholders may take a little hit with the stock price.

What do you think? Please comments!